Effect of bosentan on systemic and renal inflammatory markers in patients with diabetic nephropathy on angiotensin II receptor blockers.

Trial Profile

Effect of bosentan on systemic and renal inflammatory markers in patients with diabetic nephropathy on angiotensin II receptor blockers.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2010

At a glance

  • Drugs Bosentan (Primary)
  • Indications Diabetic nephropathies
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Actual initiation date changed from 1 Jun 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top